narlumosbart

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
narlumosbart

GtoPdb Ligand ID: 13084

Synonyms: Jinlitai® | JMT-103 | JMT103

narlumosbart is an approved drug (China (2023))

Compound class: Antibody

Comment: Narlumosbart (JMT103) is a fully human IgG4κ anti-RANKL (receptor activator of nuclear factor kappa-Β ligand) monoclonal antibody. It blocks the RANK/RANKL protein-protein interaction and thereby reduces pathological osteoclastogenesis in bone cancer.

No information available.

No information available.

Summary of Clinical Use
Narlumosbart (JMT103) was advanced as a clinical candidate for the treament of bone disorders, including osteoporosis, bone metastases from solid tumours [2] and giant cell tumor of bone (GCTB). Narlumosbart was first approved in China in September 2023, for the bone cancer indication [1].

Summary of Clinical Use

Narlumosbart (JMT103) was advanced as a clinical candidate for the treament of bone disorders, including osteoporosis, bone metastases from solid tumours [2] and giant cell tumor of bone (GCTB). Narlumosbart was first approved in China in September 2023, for the bone cancer indication [1].

Clinical Trials
Clinical Trial ID	Title	Type	Source	Comment	References
NCT05278338	Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis	Phase 2 Interventional	Shanghai JMT-Bio Inc.
NCT05813665	A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone	Phase 3 Interventional	Shanghai JMT-Bio Inc.
NCT03550508	Safety, Tolerability and PK/PD of JMT103 in Patients With Bone Metastases From Tumors	Phase 1 Interventional	Shanghai JMT-Bio Inc.		2